Module 2 – Reimbursement Strategies and Health Economics

ONE PLACE IS REMAINING FOR MODULES 2, 3 & 4 OF THIS PROGRAM. PLEASE CALL US ON 9667 8181 IF YOU’D LIKE TO PARTICIPATE.

MODULE 2

Monday 7th & Tuesday 8th August 2017

Module Schedule

Personalised Pre and Post Program Briefing with Dr Krystal Evans – at agreed times

Day 1 – Monday 7th August 2017 – can be attended by up to 3 representatives from your organisation

BioBriefing with Edward BlackReimbursement Dynamics & the Changing US Healthcare Policy

Medical technology has long been a highly regarded and rewarding enterprise. The primary factors that drive industry success have remained the same for years – creative bio-engineering, raising capital, regulatory clearance, clinical studies and publications, quality manufacturing and reimbursement. It has only been with the past three years that medical technology entrepreneurs have identified “reimbursement” as the most significant barrier to new technology adoption in the U.S. market – ahead of FDA regulatory clearance and raising capital.

This seminar will focus on the changing U.S. health care policy as it affects medical technologies and on the reimbursement fundamentals of coding, coverage and payment.

Date: Monday 7th August 2017
Time: Registration from 3:45pm for 4:00pm – 5:15pm session, followed by a networking 
Where: Bank of Melbourne, East Podium Lift, Rialto Level 2, 525 Collins Street, Melbourne

Day 2 – Tuesday 8th August 2017 to be attended by 1 representative from your organisation

Intensive Masterclass with Edward Black : Medical Technology Reimbursement: Getting Paid in the USA

– Reimbursement Essentials: coding, payment and coverage
– Product and procedure coding for new and existing technologies
– Payment methodologies and payment levels for devices, hospitals and physicians – how they are computed and the relationship between revenue and product adoption
– The process and requirements for obtaining coverage for new technologies
– The coverage conundrum: working with medicare and commercial insurers – Daniel Lace, MD, Chief Clinical Director, Reimbursement Strategies – via video conference
– The role of health economics in medical technology adoption – Melissa Martinson, PhD, President-Technomics Research, LLC – via video conference

Days 2 & 3 – 1-on-1 Sessions with Edward Black

Registration

There are 12 places available for each Module of this Program.  Priority will be given to organisations fitting the following criteria:

• Victorian based start-up or SME with less than 200 employees
• Existing validated prototype or market-ready medical technology product
• High potential for manufacture and export in next 12-24 months
• Demonstrated need for improved understanding of US market entry.

About Edward Black, President, Reimbursement Strategies, LLC

Edward Black specializes in reimbursement strategy, payer relations and health economics for medtech and biotech companies in the US and abroad. He works with companies to commercialize new products and services and has helped clients worldwide navigate the complexities of US healthcare reimbursement. Mr. Black offers a strong understanding of payer perspectives in health policy and excels in translating government and private payer policies into successful reimbursement planning.

Before founding Reimbursement Strategies, LLC in 2008, Mr. Black worked over 25 years in health and provider network management within the Blue Cross Blue Shield system and served on two national advisory boards responsible for leading consistency in medical, benefit, and payment policy. From 1994 to 2002, Edward served as the executive director of three managed care business partnerships with large multispecialty clinics for which he was awarded the 1995 Outstanding Contribution to the Healthcare Industry citation by Medical Alley Association.

Reimbursement Strategies offers the full line of medtech/biotech/pharma reimbursement services including HCPCS and CPT coding analysis and new code submissions; medical coverage policy research, analysis and advocacy; payment negotiation; clinical trial optimization for reimbursement and health economics for new and existing technologies. The company maintains relationships with most medical societies for clinical guideline development and support of CPT and ICD-10 PCS code applications. Mr. Black is active in several US and international medical technology initiatives and is a frequent international lecturer. He is a co-founder and principal in Life Sciences International, Inc. (www.lifesciencesint.com), and serves as an adjunct faculty member in the University of Minnesota Master of Science in Medical Device Innovation Program and Reimbursement Advisor to the University Office for Technology Commercialization.

Publishing Credits:
• The Journal of Urology –Cost of Neuromodulation Therapies for the Treatment of OverActive Bladder: Percutaneous Tibial Nerve Stimulation vs. Sacral Nerve Stimulation; Martinson M, MacDiarmid S, Black E. Vol. 189, 210-216, January 2013 • International Journal of Urogynecology – Cost Effectiveness of Radiofrequency Microremodeling for Stress Urinary Incontinence; Sand PK, Owens GM, Black EJ, Anderson LH, Martinson MS. 2014 Apr;25(4):517-23. doi: 10.1007/s00192-013-2230-8. Epub 2013 Oct 10. • Journal of Medical Economics – Cost-effectiveness of the Convergent Procedure and Catheter Ablation for Non-paroxysmal Atrial Fibrillation. Louise H Anderson, Edward J Black, Kenneth C Civello, Melissa S Martinson, David C Kress. July 2014, Vol 17, No. 7, Pages 481-491

Member: Medical Alley Association, Medical Industry Leadership Institute, Canada-Minnesota Business Council

Developed in consultation with:

 

 

 

 

Home

News & opinion

Member Directory

Events